Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
SOUTH SAN FRANCISCO, Calif., May 01, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its first quarter 2017 financial results on Monday, May 8, 2017 after the close of the U.S. financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Monday, May 8, 2017
- 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
- Telephone 877.719.9786 (domestic) or 719.325.4773 (international); conference ID 3868586
- Webcast available at http://public.viavid.com/index.php?id=124076
REPLAY access
- Telephone replay will be available for 30 days beginning at approximately 7:30 p.m. Eastern Time on Monday, May 8, 2017 by calling 844.512.2921 (domestic) or 412.317.6671 (international); conference ID 3868586
- Webcast replay will be available on the Achaogen website at www.achaogen.com in the Investors section and will be archived for 30 days following the presentation
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Source: Achaogen, Inc. (AKAO)
Investor Contact: Hans Vitzthum 212.915.2568 [email protected] Media Contact: Denise Powell 510.703.9491 [email protected]
